{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:54:39Z","timestamp":1762865679420,"version":"3.37.3"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/ftd.0b013e3181e5c6b3","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T09:48:49Z","timestamp":1277200129000},"page":"467-475","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic Drug Monitoring of Methotrexate in Cerebrospinal Fluid After Systemic High-Dose Infusion in Children: Can the Burden of Intrathecal Methotrexate be Reduced?"],"prefix":"10.1097","volume":"32","author":[{"given":"Andreas","family":"Niemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"M\u00fchlisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C","family":"Fr\u00fchwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Boos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3181\/00379727-93-22757","article-title":"Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma.","volume":"93","author":"Hertz","year":"1956","journal-title":"Proc Soc Exp Biol Med"},{"key":"R2-13-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1097-0142(1967)20:2<233::AID-CNCR2820200209>3.0.CO;2-8","article-title":"Continuous infusion of methotrexate in children with acute leukemia.","volume":"20","author":"Djerassi","year":"1967","journal-title":"Cancer"},{"key":"R3-13-20210129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/08880010050211321","article-title":"High-dose methotrexate in childhood ALL.","volume":"17","author":"Moe","year":"2000","journal-title":"Pediatr Hematol Oncol"},{"key":"R4-13-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00043426-198921000-00017","article-title":"Central nervous system pharmacology of antileukemic drugs.","volume":"11","author":"Balis","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R5-13-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00173684","article-title":"Pharmacologic strategies for the treatment of meningeal malignancy.","volume":"14","author":"Blaney","year":"1996","journal-title":"Invest New Drugs"},{"key":"R6-13-20210129","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1200\/JCO.2003.08.047","article-title":"CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.","volume":"21","author":"Clarke","year":"2003","journal-title":"J Clin Oncol"},{"key":"R7-13-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0950-3536(05)80208-2","article-title":"Long-term sequelae of therapy for childhood acute lymphoblastic leukaemia.","volume":"7","author":"Ochs","year":"1994","journal-title":"Baillieres Clin Haematol"},{"key":"R8-13-20210129","first-page":"176","article-title":"Is high dose methotrexate without irradiation of the brain sufficiently effective in prevention of CNS disease in children with acute lymphoblastic leukemia?","volume":"45","author":"Cap","year":"1998","journal-title":"Neoplasma"},{"key":"R9-13-20210129","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation.","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"R10-13-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mph.0000168729.32463.7b","article-title":"Prospective evaluation of clinical and laboratory effects of intrathecal chemotherapy on children with acute leukemia.","volume":"27","author":"Keidan","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R11-13-20210129","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"key":"R12-13-20210129","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","article-title":"Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates.","volume":"48","author":"Hryniuk","year":"1969","journal-title":"J Clin Invest"},{"key":"R13-13-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D","article-title":"A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g\/m2 in children with acute lymphoblastic leukemia.","volume":"60","author":"Borsi","year":"1987","journal-title":"Cancer"},{"key":"R14-13-20210129","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/CAD.0b013e3281430bd1","article-title":"Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.","volume":"18","author":"Jonsson","year":"2007","journal-title":"Anticancer Drugs"},{"key":"R15-13-20210129","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J Clin Oncol"},{"key":"R16-13-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/08880019009034320","article-title":"Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkins lymphoma.","volume":"7","author":"Vassal","year":"1990","journal-title":"Pediatr Hematol Oncol"},{"key":"R17-13-20210129","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0277-5379(90)90023-M","article-title":"CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g\/m2 methotrexate. A study from the EORTC Childrens Leukemia Cooperative Group.","volume":"26","author":"Milano","year":"1990","journal-title":"Eur J Cancer"},{"key":"R18-13-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199409049660","article-title":"Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g\/m2 methotrexate.","volume":"14","author":"Millot","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"R19-13-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0145-2126(99)00181-2","article-title":"Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.","volume":"24","author":"Seidel","year":"2000","journal-title":"Leuk Res"},{"key":"R20-13-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/clpt.1983.37","article-title":"Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.","volume":"33","author":"Evans","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"R21-13-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/08880018809031261","article-title":"Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction.","volume":"5","author":"Lippens","year":"1988","journal-title":"Pediatr Hematol Oncol"},{"key":"R22-13-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"key":"R23-13-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00003088-200241030-00002","article-title":"Strategies for increasing drug delivery to the brain: focus on brain lymphoma.","volume":"41","author":"Siegal","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R25-13-20210129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1227\/00006123-199604000-00019","article-title":"The significance of artificial cerebrospinal fluid as perfusate and endoneurosurgery.","volume":"38","author":"Oka","year":"1996","journal-title":"Neurosurgery"},{"key":"R26-13-20210129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1985.3.4.485","article-title":"Remission induction of meningeal leukemia with high-dose intravenous methotrexate.","volume":"3","author":"Balis","year":"1985","journal-title":"J Clin Oncol"},{"key":"R27-13-20210129","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0277-5379(87)90289-6","article-title":"Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.","volume":"23","author":"Thyss","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R28-13-20210129","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jps.2600800804","article-title":"Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.","volume":"80","author":"Chatelut","year":"1991","journal-title":"J Pharm Sci"},{"key":"R29-13-20210129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3171\/jns.1999.91.2.0221","article-title":"Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.","volume":"91","author":"Hiraga","year":"1999","journal-title":"J Neurosurg"},{"key":"R30-13-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mpo.2950240303","article-title":"Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.","volume":"24","author":"Donelli","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"R31-13-20210129","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","article-title":"7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.","volume":"57","author":"Jacobs","year":"1976","journal-title":"J Clin Invest"},{"key":"R32-13-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","article-title":"Methotrexate: clinical pharmacology, current status and therapeutic guidelines.","volume":"4","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rev"},{"key":"R33-13-20210129","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0304-3835(80)90117-2","article-title":"The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy.","volume":"9","author":"Lankelma","year":"1980","journal-title":"Cancer Lett"},{"key":"R34-13-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0731-7085(84)80090-4","article-title":"Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study.","volume":"2","author":"Fabre","year":"1984","journal-title":"J Pharm Biomed Anal"},{"key":"R35-13-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/mpo.2950180310","article-title":"Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g\/m2 to children with acute lymphoblastic leukemia.","volume":"18","author":"Borsi","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"R36-13-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ijc.2910420125","article-title":"High-dose methotrexate: methotrexate and 7-hydroxymethotrexate diffusion in cerebrospinal fluid.","volume":"42","author":"Payet","year":"1988","journal-title":"Int J Cancer"},{"key":"R37-13-20210129","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI107362","article-title":"Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.","volume":"52","author":"Chabner","year":"1973","journal-title":"J Clin Invest"},{"key":"R38-13-20210129","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate.","volume":"309","author":"Jolivet","year":"1983","journal-title":"N Engl J Med"},{"key":"R39-13-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(25)30311-3","article-title":"Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion.","volume":"195","author":"Blasberg","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"R40-13-20210129","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJM197310112891503","article-title":"Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia.","volume":"289","author":"Bleyer","year":"1973","journal-title":"N Engl J Med"},{"key":"R41-13-20210129","first-page":"703","article-title":"Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.","volume":"61","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"R42-13-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00043426-198921000-00019","article-title":"Neurotoxicity due to central nervous system therapy for childhood leukemia.","volume":"11","author":"Ochs","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R43-13-20210129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.mph.0000162527.85024.e9","article-title":"Myelopathy due to intrathecal chemotherapy: report of six cases.","volume":"27","author":"Bay","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R44-13-20210129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/pbc.20861","article-title":"Intracerebral hematoma as a complication of intrathecal methotrexate administration.","volume":"50","author":"Boran","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R45-13-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200544010-00001","article-title":"Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.","volume":"44","author":"Fleischhack","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R46-13-20210129","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/1097-0142(19821101)50:9<1676::AID-CNCR2820500903>3.0.CO;2-S","article-title":"Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkins lymphoma.","volume":"50","author":"Ettinger","year":"1982","journal-title":"Cancer"},{"key":"R47-13-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM198602203140803","article-title":"Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.","volume":"314","author":"Evans","year":"1986","journal-title":"N Engl J Med"},{"key":"R48-13-20210129","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.1987.5.12.2017","article-title":"High-dose methotrexate: a critical reappraisal.","volume":"5","author":"Ackland","year":"1987","journal-title":"J Clin Oncol"},{"key":"R49-13-20210129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","article-title":"Current management and challenges of malignant disease in the CNS in paediatric leukaemia.","volume":"9","author":"Pui","year":"2008","journal-title":"Lancet Oncol"},{"key":"R50-13-20210129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2003.04.096","article-title":"Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture.","volume":"21","author":"Burger","year":"2003","journal-title":"J Clin Oncol"},{"key":"R51-13-20210129","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"R52-13-20210129","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.","volume":"27","author":"Brugieres","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181e5c6b3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T03:57:41Z","timestamp":1740196661000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201008000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181e5c6b3","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}